ASCO GUIDELINES Bundle

Antiemetics (CINV)

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/856867

Contents of this Issue

Navigation

Page 8 of 17

9 Table 3. Antiemetic Dosing for Adults by Chemotherapy Risk Category Emetic Risk Category Dose on Day of Chemotherapy Dose on Subsequent Days High: Cisplatin and other agents NK 1 receptor antagonist Aprepitant 125 mg oral 80 mg oral on days 2–3 Fosaprepitant 150 mg IV Netupitant-palonosetron 300 mg netupitant/0.5 mg palonosetron oral in single capsule (NEPA) Rolapitant 180 mg oral 5-HT 3 receptor antagonist a Granisetron 2 mg oral or 1 mg or 0.01 mg/kg IV or 1 transdermal patch or 10 mg subcutaneous Ondansetron 8 mg oral twice daily or 8 mg oral dissolving tablet twice daily or three 8 mg oral soluble films or 8 mg or 0.15 mg/kg IV Palonosetron 0.50 mg oral or 0.25 mg IV Dolasetron 100 mg oral ONLY Tropisetron 5 mg oral or 5 mg IV Ramosetron 0.3 mg IV Dexamethasone If aprepitant is used b 12 mg oral or IV 8 mg oral or IV once daily on days 2–4 If fosaprepitant is used b 12 mg oral or IV 8 mg oral or IV on day 2; 8 mg oral or IV twice daily on days 3–4 If netupitant- palonosetron is used b 12 mg oral or IV 8 mg oral or IV once daily on days 2–4 If rolapitant is used 20 mg oral or IV 8 mg oral or IV twice daily on days 2–4 Olanzapine 10 mg oral 10 mg oral on days 2–4 High: Anthracycline combined with cyclophosphamide c NK 1 receptor antagonist Aprepitant 125 mg oral 80 mg oral on days 2–3 Fosaprepitant 150 mg IV

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Antiemetics (CINV)